Fully biologically active when compared to standard. The ED50 as determined by its ability to inhibit the TNF-α mediated cytotoxicity in the L-929 cells is less than 2μg/ml, corresponding to a specific activity of >500IU/mg in the presence of 0.1ng/ml of rMuTNF-α.
Physical Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation
Lyophilized from a 0.2μm filtered solution in PBS, pH7.4.
Endotoxin
Less than 0.1EU/μg of rMusTNF RII/TNFRSF1B as determined by LAL method.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤-20℃. Further dilutions should be made in appropriate buffered solutions.
Category
Cytokine
Background
TNFRSF1B also known as tumor necrosis factor receptor 2 (TNFR2) and CD120b, is encoded by the TNFRSF1B gene in humans. It is a member of the tumor necrosis factor receptor superfamily, which also contains TNFRSF1A. This protein and TNF-receptor 1 form a heterocomplex that mediates the recruitment of two anti-apoptotic proteins, c-IAP1 and c-IAP2, which possess E3 ubiquitin ligase activity. TNFRSF1B has been shown to interact with TRAF2 and TTRAP. Recombinant murine TNFRSF1B is a 25.3kDa protein with 236 amino acid residues.
